IgA response by oral infection with an attenuated Yersinia enterocolitica mutant: Implications for its use as oral carrier vaccine

Vaccine

Volumn 26, Issue 51, 2008, Pages 6497-6502

  Blanco, Helga M ^a   Lacoste, María G ^a   Eliçabe, Ricardo J ^a   Di Genaro, María S ^a  

^a UNIVERSIDAD NACIONAL DE SAN LUIS   (Argentina)

Author keywords

IgA response; Oral carrier vaccines; Yersinia enterocolitica sycH

Indexed keywords

IMMUNOGLOBULIN A; PROTEIN YOPH; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; BACTERIUM MUTANT; CONTROLLED STUDY; IMMUNE DEFICIENCY; IMMUNE RESPONSE; MOUSE; MOUTH INFECTION; MUCOSAL IMMUNITY; NONHUMAN; PEYER PATCH; PRIORITY JOURNAL; PROTEIN SECRETION; VACCINATION; VIRUS ATTENUATION; YERSINIA ENTEROCOLITICA; YERSINIOSIS;

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; FECES; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; INTERLEUKIN-4; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUTATION; PEYER'S PATCHES; YERSINIA ENTEROCOLITICA; YERSINIA INFECTIONS;

EID: 58149186671     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.09.046     Document Type: Article

References (34)

1. Cornelis G.R., Boland A., Boyd A.P., Geuijen C., Iriarte M., Neyt C., et al. The virulence plasmid of Yersinia, an antihost genome. Microbiol Mol Biol Rev 62 4 (1998) 1315-1352
2. Alonso A., Bottini N., Bruckner S., Rahmouni S., Willimas S., Shoenberger S.P., et al. Lck dephosphorylation at Tyr-394 and inhibition of T cell antigen receptor signaling by Yersinia phosphatase YopH. J Biol Chem 279 6 (2004) 4922-4928
3. Persson C., Carballeira N., Wolf-Watz H., and Fallman M. The PTPase YopH inhibits uptake of Yersinia, tyrosine phosphorylation of p130Cas and FAK, and the associated accumulation of these proteins in peripheral focal adhesions. EMBO J 16 9 (1997) 2307-2318
4. Yao T., Mecsas J., Healy J.I., Falkow S., and Chien Y. Supression of T and B lymphocyte activation by a Yersinia pseudotuberculosis virulence factor, yopH. J Exp Med 190 9 (1999) 1343-1350
5. Autenrieth I.B., and Firsching R. Penetration of M cells and destruction of Peyer's patches by Yersinia enterocolitica: an ultrastructural and histological study. J Med Microbiol 44 4 (1996) 285-294
6. Autenrieth I.B., Kempf V., Sprinz T., Preger S., and Schnell A. Defense mechanisms in Peyer's patches and mesenteric lymph nodes against Yersinia enterocolitica involve integrin and cytokines. Infect Immun 64 4 (1996) 1357-1368
7. Autenrieth I.B., Vogel U., Preger S., Heymer B., and Heesemann J. Experimental Yersinia enterocolitica infection in euthymic and T-cell-deficient athymic nude C57BL/6 mice: comparison of time course, histomorphology, and immune response. Infect Immun 61 6 (1993) 2585-2595
8. + T cells. J Immunol 156 4 (1996) 1458-1468
9. Di Genaro M.S., Waidmann M., Kramer U., Hitziger N., Bohn E., and Autenrieth I.B. Attenuated Yersinia enterocolitica mutant strains exhibit differential virulence in cytokine-deficient mice: implications for the development of novel live carrier vaccines. Infect Immun 71 4 (2003) 1804-1812
10. de Jong R., Altare F., Haagen I.A., Elferink D.G., Boer T., van Breda Vriesman P.J., et al. Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. Science 280 5368 (1998) 1435-1438
11. Russmann H., Gerdemann U., Igwe E.I., Panthel K., Heesemann J., Garbom S., et al. Attenuated Yersinia pseudotuberculosis carrier vaccine for simultaneous antigen-specific CD4 and CD8 T-cell induction. Infect Immun 71 6 (2003) 3463-3472
12. Sory M.P., and Cornelis G.R. Delivery of the cholera toxin B subunit by using a recombinant Yersinia enterocolitica strain as a live oral carrier. Res Microbiol 141 7-8 (1990) 921-929
13. Autenrieth S.E., and Autenrieth I.B. Yersinia enterocolitica: subversion of adaptive immunity and implications for vaccine development. Int J Med Microbiol 298 1-2 (2008) 69-77
14. Holmgren J., and Czerkinsky C. Mucosal immunity and vaccine. Nat Med 11 4 (2005) S45-53
15. Xu-Amano J., Kiyono H., Jackson R., Staats H., Fujihashi K., Burrows P., et al. Helper T cell subsets for immunoglobulin A responses: oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues. J Exp Med 178 4 (1993) 1309-1320
16. Heesemann J., Keller C., Morawa R., Schmidt N., Siemens H.J., and Laufs R. Plasmids of human strains of Yersinia enterocolitica: molecular relatedness and possible importance for pathogenesis. J Infect Dis 147 1 (1983) 107-115
17. Ruckdeschel K., Roggenkamp A., Schubert S., and Heesemann J. Differential contribution of Yersinia enterocolitica virulence factors to evasion of microbicidal action of neutrophils. Infect Immun 64 3 (1996) 724-733
18. Trček J., Wilharm G., Jacobi C.A., and Heesemann J. Yersinia enterocolitica Yop Q: strain-dependent cytosolic accumulation and post-translational secretion. Microbiology 148 Pt 5 (2002) 1457-1465
19. Pfeffer K., Matsuyama T., Kunding T.M., Wakeham A., Kishihara K., Shahinian A., et al. Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection. Cell 73 3 (1993) 457-467
20. Magram J., Connaughton S.E., Warrier R.R., Carvajal D.M., Wu C.Y., Ferrante J., et al. IL-12-deficient mice are defective in IFN gamma production and type I cytokine responses. Immunity 4 5 (1996) 471-481
21. Kuhn R., Rajewsky K., and Muller W. Generation and analysis of interleukin-4 deficient mice. Science 254 5032 (1991) 707-710
22. Vajdy M., Kosco-Vilbois M.H., Kopf M., Köhler G., and Lycke N. Impaired mucosal immune responses in interleukin 4-targeted mice. J Exp Med 181 1 (1995) 41-53
23. Elson C.O., and Ealding W. Generalized systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin. J Immunol 132 6 (1984) 2736-2741
24. Lycke N., and Holmgren J. Strong adjuvant properties of cholera toxin on gut mucosal immune responses to orally presented antigens. Immunology 59 2 (1986) 301-308
25. Frey J. Biological safety concepts of genetically modified live bacterial vaccine. Vaccine 25 30 (2007) 5598-5605
26. Curtiss III R. Bacterial infectious disease control by vaccine development. J Clin Invest 110 8 (2002) 1061-1066
27. Trülzsch K., Sporleder T., Igwe E.I., Rüssmann H., and Heesemann J. Contribution of the major secreted yops of Yersinia enterocolitica O:8 to pathogenicity in the mouse infection model. Infect Immun 72 9 (2004) 5227-5234
28. Moyle P.M., McGeary R.P., Blanchfield J.T., and Toth I. Mucosal immunisation: adjuvants and delivery systems. Curr Drug Deliv 1 4 (2004) 385-396
29. Dertazbaugh M.T., and Elson C.O. Cholera toxin as a mucosal adjuvant. In: Spriggs D.R., and Koff W.C. (Eds). Topic in vaccine adjuvant research (1991), CRC Press, Inc., Boca Raton, FL 119-131
30. Autenrieth I.B., and Schmidt M.A. Bacterial interplay at intestinal mucosal surfaces: implications for vaccine development. Trends Microbiol 8 10 (2000) 457-464
31. Yamamoto M., Kweon M.N., Rennert P.D., Hiroi T., Fujihashi K., McGhee J.R., et al. Role of gut-associated lymphoreticular tissues in antigen-specific intestinal IgA immunity. J Immunol 173 2 (2004) 762-769
32. Simmons C.P., Goncalves N.S., Ghaem-Maghami M., Bajaj-Elliott M., Clare S., Neves B., et al. Impaired resistance and enhanced pathology during infection with a noninvasive, attaching-effacing enteric bacterial pathogen, Citrobacter rodentium, in mice lacking IL-12 or IFN-γ. J Immunol 168 4 (2002) 1804-1812
33. + Th2 cells producing IL-6 and IL-10 are associated with mucosal immunoglobulin A responses. Infect Immun 64 5 (1996) 1516-1525
34. Khan S., Chatfield S., Stratford R., Bedwell J., Bentley M., Sulsh S., et al. Ability of SPI2 mutant of S. thyphi to effectively induce antibody responses to the mucosal antigen enterotoxigenic E. coli heat labile toxin B subunit after oral delivery to humans. Vaccine 25 21 (2007) 4175-4182